Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.6% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care, Inc. (TNDM) is a company specializing in diabetes management solutions, including insulin pumps and related technologies. The stock had a strong bullish movement today amidst various news developments.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 5.6% on Mar 19, 2026 14:10

• Despite reporting a Q4 loss, Tandem Diabetes Care exceeded revenue expectations, showcasing strong growth in its top line.
• The exercise of Restricted Stock Units by company executives and insiders selling shares may have initially caused some downward pressure on the stock price.
• A stock upgrade by Piper Sandler and a positive market outlook contributed to the bullish movement, reflecting investor confidence in the company's future prospects.
• The detailed financial overview and competitor comparison provided insights into Tandem Diabetes Care's revenue sources and financial health, potentially reassuring investors and contributing to the positive market sentiment.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem Diabetes Care, Inc. (TNDM) reports Q4 loss, tops revenue estimates

Tandem Diabetes Care (TNDM) reported a Q4 loss of $0.62 per share, which was wider than the Zacks Consensus Estimate but a significant improvement from the previous year. The company's revenue of $197.6 million surpassed analyst expectations and also grew year-over-year. Despite the revenue beat, the stock opened lower following the announcement.

https://www.msn.com/en-us/money/topstocks/tandem-diabetes-care-inc-tndm-reports-q4-loss-tops-revenue-estimates/ar-AA1WHdaF

Tandem Diabetes (TNDM) EVP exercises 7,414 RSUs and sells 187 shares

Tandem Diabetes Care's EVP & Chief Commercial Officer, Mark David Novara, exercised 7,414 Restricted Stock Units, resulting in the vesting of common shares under the company's 2023 Long-Term Incentive Plan. To cover taxes, 5,540 shares were withheld by the company, and Novara also made a separate pre-scheduled open-market sale of 187 common shares at $23.05 each. After these transactions, Novara directly holds 37,656 shares of Tandem Diabetes Care common stock.

https://www.stocktitan.net/sec-filings/TNDM/form-4-tandem-diabetes-care-inc-insider-trading-activity-37b1a0d8ab2b.html

Tandem Diabetes Care (TNDM) insider files resale notice; 2 shares sold at $45.62

A Tandem Diabetes Care (TNDM) insider has filed a Form 144 notice for a proposed resale of 187 shares originating from Restricted Stock Units, effective March 15, 2026. The filing also reports a small 10b5-1 sale of 2 shares at $45.62 on March 5, 2026, by Mark Novara through Morgan Stanley Smith Barney LLC. This filing is considered routine given the small quantity of shares involved.

https://www.stocktitan.net/sec-filings/TNDM/144-tandem-diabetes-care-inc-sec-filing-f4abc497899b.html

Tandem Diabetes Care Stock Upgrade & Market Outlook 2026 - News and Statistics

Shares of Tandem Diabetes Care (TNDM) rose after Piper Sandler upgraded the company's stock and set a higher price target, contributing to positive market sentiment. Despite this recent gain, the stock has experienced significant volatility and is still below its earlier peak, with a five-year investment showing a decline in value. The article also includes extensive details about a global syringe industry report, forecasting demand, supply, and trade flows to 2035.

https://www.indexbox.io/blog/tandem-diabetes-care-stock-rises-after-piper-sandler-upgrade/

TNDM Financials: Revenue Breakdown, Margins & Competitor Comparison

This article provides a financial overview of Tandem Diabetes Care Inc (TNDM), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company primarily generates revenue from its Pump segment, and its financial health is assessed through metrics like gross margin, operating margin, and return on equity. TNDM's performance is benchmarked against industry peers like PLSE and ATRC.

https://intellectia.ai/en/stock/TNDM/financials

Trending Today

Mosaic Company (The) ($MOS) Stock Forecast: Down 9.3% Today

QuantumScape Corp. ($QS) Stock Forecast: Down 5.5% Today

FuelCell Energy ($FCEL) Stock Forecast: Down 5.4% Today

Peloton Interactive Inc ($PTON) Stock Forecast: Down 5.7% Today

Kimco Realty Corporation ($KIM) Stock Forecast: Down 3.5% Today

SL Green Realty Corp ($SLG) Stock Forecast: Down 5.2% Today

StoneCo Ltd. ($STNE) Stock Forecast: Down 5.2% Today

Cleveland-Cliffs Inc. ($CLF) Stock Forecast: Down 5.0% Today

American Airlines Group Inc. ($AAL) Stock Forecast: Down 5.4% Today

TKO Group Holdings Inc ($TKO) Stock Forecast: Down 5.2% Today

Tandem Diabetes Care, Inc. Price History

24.01.2026 - TNDM Stock was up 5.3%

• Tandem Diabetes Care's bullish movement today could be attributed to the positive market reception of its proposed private placement of convertible notes, signaling investor confidence in the company's growth prospects.
• The upgrade of Tandem Diabetes Care's stock rating by Lake Street Capital Markets, driven by the successful transition to a pharmacy distribution model, likely contributed to the bullish sentiment surrounding the company.
• The projected significant growth of the global insulin delivery devices market, with insulin pumps expected to dominate the market share, could have also positively influenced Tandem Diabetes Care's stock performance as a key player in this industry.
• Overall, the combination of strategic financial moves, positive analyst outlook, and favorable market trends in the healthcare sector likely fueled Tandem Diabetes Care's strong bullish movement today.

10.02.2026 - TNDM Stock was up 6.2%

• Tandem Diabetes Care's positive momentum is due to the launch of the Mobi insulin pump for Android users, expanding accessibility and convenience.
• The company's strategic move to make its Control-IQ+ technology compatible with a broader range of devices aligns with the industry's shift toward smartphone-operated automated insulin delivery systems.
• Favorable analyst attention, such as a price target increase and stock rating upgrade, has bolstered investor confidence in Tandem Diabetes Care's growth potential.
• With the recent completion of a $265 million convertible bond offering, the company's funding and valuation landscape has been reshaped, offering flexibility for future growth but also raising concerns about potential share dilution. It is advisable for investors to monitor the company's utilization of these funds in comparison to its current financial performance.

23.01.2026 - TNDM Stock was up 10.1%

• Tandem Diabetes Care's stock witnessed a surge of over 32% due to record margins and a revenue beat, supported by strong demand for its insulin pumps and enhanced gross margin.
• An upgrade by Lake Street Capital Markets to a Buy rating with a price target of $50.00 bolstered investor confidence, underscoring the company's successful shift to a pharmacy distribution model.
• The projected growth of the global insulin delivery devices market, particularly in insulin pumps leading the market share, also contributed to positive sentiment surrounding Tandem Diabetes Care.
• A combination of robust financial performance, margin expansion, and positive sales forecasts for 2026 resulted in a short squeeze and a notable increase in Tandem Diabetes Care's stock price.

23.01.2026 - TNDM Stock was up 6.3%

• Tandem Diabetes Care (TNDM) saw a remarkable 33% surge in its stock performance today, propelled by exceptional margins and outperforming revenue figures, prompting a short squeeze and a notable price upswing.
• The company delivered robust results in the fourth quarter, driven by a strong demand for its insulin pumps and an enhanced gross margin, contributing to the significant rise in its stock value.
• With an innovative pay-as-you-go pharmacy model that is augmenting margin expansion and generating recurring revenue, Tandem Diabetes Care is well-positioned for sustained profitable growth in 2026, with anticipated sales ranging between $1.065 billion and $1.085 billion.
• Tandem Diabetes Care's strategic initiatives for future expansion, such as the emphasis on the "pay-as-you-go" approach and the projected increase in pump shipments for 2026, have elicited positive responses from investors and analysts, despite a slightly lower-than-expected sales forecast for the fiscal year 2026.

25.01.2026 - TNDM Stock was down 7.8%

• The disclosure of pricing and upsizing details of the private placement of convertible senior notes due in 2032 likely sparked investor worries about possible share dilution, contributing to the prevailing bearish sentiment.
• Despite the favorable development of a stock rating upgrade by Lake Street Capital Markets attributed to a successful transition to a pharmacy distribution model, the attention on the convertible notes offering appeared to overshadow the favorable shift in the company's business approach.
• Investors are possibly exercising caution regarding the company's intention to utilize the proceeds for potential acquisitions, raising uncertainties about future growth and profitability.
• Market response suggests that while the strategic shift's long-term advantages are acknowledged, immediate concerns regarding share dilution and capital deployment choices are exerting a negative influence on the stock's performance.

19.02.2026 - TNDM Stock was up 5.6%

• Despite reporting a Q4 loss, Tandem Diabetes Care exceeded revenue expectations, showcasing strong growth in its top line.
• The exercise of Restricted Stock Units by company executives and insiders selling shares may have initially caused some downward pressure on the stock price.
• A stock upgrade by Piper Sandler and a positive market outlook contributed to the bullish movement, reflecting investor confidence in the company's future prospects.
• The detailed financial overview and competitor comparison provided insights into Tandem Diabetes Care's revenue sources and financial health, potentially reassuring investors and contributing to the positive market sentiment.

27.01.2026 - TNDM Stock was down 5.1%

• Reduction of stake by Envestnet Asset Management Inc. by 15% could have signaled lack of confidence in the company's future prospects, contributing to the bearish movement.
• Despite beating quarterly EPS and revenue estimates, the fact that Tandem Diabetes Care remains unprofitable might have raised concerns among investors, leading to the downward trend in the stock price.
• The pricing of an upsized private placement of convertible senior notes due 2032 could have diluted the value of existing shares, impacting the stock negatively.
• Mixed signals from analysts, with a "Hold" rating and a consensus target price of $28.00, might have added uncertainty to investors, influencing the bearish movement in the stock.

06.02.2026 - TNDM Stock was down 5.2%

• The expansion of Tandem's Mobi automated insulin delivery system to Android smartphones, while a positive development for accessibility and user convenience, may have raised concerns about potential competition in the market, leading to a bearish sentiment among investors.
• Despite receiving rating upgrades and achieving over $1 billion in worldwide sales, the market may have reacted negatively to the stock due to profit-taking by investors who were anticipating a bullish run following these positive developments.
• The announcement of further innovations planned for 2026, including a tubeless Mobi pump and an advanced insulin algorithm, could have created uncertainty among investors about the company's ability to maintain its current growth trajectory, contributing to the bearish movement in the stock price.

17.02.2026 - TNDM Stock was up 7.3%

• The positive movement in TNDM stock today could be linked to the company's new product releases, such as insulin pump software and the introduction of Tandem Mobi.
• Despite industry competition and economic challenges, TNDM's solid financial position and emphasis on advanced solutions appear to have appealed to investors.
• The recent net loss in the fourth quarter of 2025 might have been overlooked due to the perceived long-term growth prospects of Tandem Diabetes, contributing to the optimistic sentiment in the market today.

05.02.2026 - TNDM Stock was down 5.4%

• The introduction of Tandem Mobi's compatibility with Android smartphones, potentially broadening its user base, could have prompted concerns about technical issues or integration challenges, leading to uncertainty among investors and selling pressure on the stock.
• Despite receiving favorable analyst upgrades and surpassing $1 billion in worldwide sales, doubts voiced in the healthcare sector may have influenced market sentiment toward Tandem Diabetes Care, contributing to its recent stock decline.
• Anticipation surrounding the company's upcoming innovations in 2026, such as a tubeless Mobi pump and an enhanced insulin algorithm, may have raised expectations while also introducing uncertainty about execution and market reception, resulting in a negative impact on the stock price.
• When considering the expanded market reach, positive ratings, financial achievements, and industry doubts, the collective effect might have created varying investor sentiments, ultimately leading to the recent decline in TNDM stock value.

03.02.2026 - TNDM Stock was down 5.7%

• A decline in TNDM stock value is likely due to investors selling their shares to lock in profits following a period of positive updates and price increases.
• Despite achieving over $1 billion in worldwide sales and receiving analyst rating upgrades, concerns of future financial obligations arose when the company issued $300 million in zero-coupon convertible notes due 2032, potentially leading to stock pullback.
• Mixed financial results, including a reported net loss for the half-year and challenges related to a high debt-equity ratio, may have further fueled the negative investor sentiment surrounding TNDM stock.

11.02.2026 - TNDM Stock was up 6.5%

• The bullish movement in TNDM stock today is due to the positive market reception of the company's expansion of the Mobi automated insulin delivery system to Android users. This move has significantly widened the potential user base for Tandem's technology, reflecting a strategic decision to tap into a larger market segment.
• Vanguard Group Inc.'s decision to trim its position in TNDM by 4.2% may have initially raised concerns among investors. However, the market sentiment was likely buoyed by the company's better-than-expected earnings report for the latest quarter, showcasing strong financial performance despite remaining unprofitable.
• The increased analyst attention, with Truist Securities raising its price target and Lake Street Capital Markets upgrading the stock to a Buy rating, also contributed to the positive momentum in TNDM stock, indicating growing confidence in the company's growth prospects and technological advancements in the diabetes management sector.
• Overall, Tandem Diabetes Care's strategic expansion into the Android market, coupled with favorable analyst ratings and robust financial performance, has fueled investor optimism and driven the bullish movement in the stock today.